Skip to main content
OpenTrials
Completed

NCT Number: NCT04848402

A Device Study in Healthy Participants

The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given. The study will last up to five weeks for each participant, including a one-week overnight stay in the study center.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

LABCORP

Leeds, LS2 9LH, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Overtly healthy male or female participants as determined by medical history, laboratory tests, physical examination, 12-lead ECGs, and vital signs.
  • Body mass index (BMI) within the range of 18 to 32 kilograms per meter squared (kg/m²)
  • Female participants must not be pregnant, and must test negative for pregnancy
  • Agree to video recording during each administration event using the autoinjector or bolus injector

Exclusion criteria

  • Have known allergies to any components of the placebo or related compounds, or history of significant atopy, or known allergies or irritation to adhesives (e.g. skin adhesives, band aid)
  • Have an abnormal blood pressure as determined by the investigator
  • Have a history or presence of a bleeding disorder
  • Have a history of any types of neuropathy, radiculopathy, or fibromyalgia that would affect perception in abdominal wall
  • Have self-perceived dullness or loss-of-sensation on either side of the body or the abdomen
  • Have any condition that could affect pain perception from an injection
  • Have tattoos or scars over the abdomen, or other factors (eg, rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection-site assessments
  • Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the trial
  • Are currently using or intend to use painkillers, aspirin, or other nonsteroidal Anti-inflammatory drugs, anticoagulant or antiaggregant drugs, over-the-counter or prescription medication for pain or inflammation
  • Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 2 months or 5 half-lives (whichever is longer) should have passed
  • Are unwilling to stop alcohol consumption
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Are unwilling to abide by the tobacco restrictions
  • Poor peripheral venous access
  • Have a pacemaker and/or similar devices/other implantables

Treatment and study plan

On-Body Delivery System (OBDS)/Multiple Bolus Injector

Device

Used to administer placebo SC.

Single Auto Injector

Device

Used to administer placebo SC.

Placebo

Drug

Administered SC.

Primary outcomes

  1. Number of Participants with One or More Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Device

    Time frame: Baseline through day 7

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Study to Investigate the Safety and Tolerability of a Wearable On-body Delivery System, and Exploratory Assessment of Participant Response With an Autoinjector, Following Subcutaneous Injections of Placebo in Healthy Participants

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 19, 2021
Registry last updated
Mar 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.